Biophytis Sa · EURONEXT:ALBPS
Biophytis Sa — IPO Roadshow (February 2021)
18 slides from Biophytis Sa's IPO roadshow presentation, Feb 3, 2021
Slide 1: Issuer Free Writing Prospectus
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333 - 252225 February 2, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements 2 All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goa
Slide 3: Free Writing Prospectus Statement
Free Writing Prospectus Statement 3 This presentation highlights basic information about us and the offering to which this communication relates. We have filed a registration statement on Form F - 1 (including a preliminary prospectus) with the SEC for the offering to which this presentation relates
Slide 4: Prevent disabilities and increase health span for patients with age-related diseases
4 Prevent disabilities (muscular, respiratory and vision) and increase health span for patients suffering from age - related diseases Our small molecules are aimed at stimulating biological resilience and are d eveloped through a drug discovery platform based on a reverse pharmacology approach COVID
Slide 5: Executive team
Executive team Stanislas Veillet - Founder & CEO • PhD in genetics, AgroParisTech • 25+ years in biotech; Pharmacia - Monsanto, Danone Group Pierre Dilda - CSO • PhD in pharmacology (Paris V) • 25 years experience in pharmaceutical research, in both academic and industrial settings Samuel Agus - CMO
Slide 6: Our clinical pipeline
Our clinical pipeline 6 • Second generation drug candidates, BIO103 and BIO203, are life - cycle extension candidates in the preclinical Phase Sarconeos (BIO101) Macuneos (BIO201) Candidate Indication Preclinical Covid - 19 DMD Program COVA MYODA Dry AMD Stargardt MACA Sarcopenia SARA Phase 1 Phase
Slide 7: Sarconeos (BIO101) is believed to activate MAS receptor
Sarconeos (BIO101) is believed to activate MAS receptor, a key factor for muscle and respiratory functions • MAS receptor: a key component of the Re nin - Angiotensin System (RAS) • Triggers two important downstream signaling - pathways in myocytes: PI3K/AKT/mTOR: Increases protein synthesis, preser
Slide 8: Sarconeos (BIO101) for respiratory failure in COVID-19
8 Sarconeos (BIO101) for respiratory failure in COVID - 19 • SARS - CoV - 2 uses ACE2 to penetrate the lungs destabilizing RAS system and causing respiratory failures • Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS system
Slide 9: Sarconeos improves muscle strength and mobility in animal model
We believe Sarconeos (BIO101) improves muscle strength and mobility in animal model Administration of 50 mg/kg/day of Sarconeos (BIO101) demonstrated a statistically significant (p<0.01) improvement in maximum running velocity (Vmax) c ompared to “old” control mice, c ompensating almost completely f
Slide 10: Early data suggests Sarconeos improves respiratory functions in animal model
Early data suggests Sarconeos (BIO101) improves respiratory functions in animal model Chronic (8 week) daily administration of 50 mg/kg/day of Sarconeos (BIO101) statistically significantly (p<0.001) improved lungs mechanical properties measured by airway resistance Improves lungs mechanical propert
Slide 11: Sarconeos results in Phase 1 study (SARA-PK) in elderly healthy volunteers
Sarconeos (BIO101) results in Phase 1 study (SARA - PK) in elderly healthy volunteers Sarconeos (BIO101) showed a dose dependent effect on muscle growth and repair (PIIINP) and a dose dependent negative effect on muscle wasting (myoglobin) • Single and multiple ascending doses tested in 54 healthy a
Slide 12: Sarcopenia: a large unmet medical need with no currently approved drugs
Sarcopenia: a large unmet medical need with no currently approved drugs • Age - related degeneration of skeletal muscle characterized by a loss of muscle mass, strength and functional issues such as the ability to stand and/or walk • A major cause of mobility disability, resulting in a loss of indep
Slide 13: SARA-INT: Phase 2 clinical trial in sarcopenia
SARA - INT: Phase 2 clinical trial in sarcopenia • Global, double - blind, randomized, placebo - controlled trial: NCT03452488 • Recruitment completed March 2020 for 233 elderly patients with sarcopenia at risk of mobility disability over 22 centers in the US and Belgium Objectives Key Endpoints Sub
Slide 14: SARA-INT: topline results expected in Q2 2021
SARA - INT: topline results expected in Q2 2021 14 Recruitment Dr. Roger Fielding , PhD, Director of the Nutrition, Exercise Physiology & Sarcopenia Laboratory at Tufts University in Boston and Principal Investigator of SARA - INT trial “ The SARA - INT Phase 2 trial is investigating a new treatment
Slide 15: COVA Study: targeting hospitalized patients with respiratory failure
COVA Study: targeting hospitalized patients with respiratory failure, and not intubated • Patients aged 45 and above , with proven COVID - 19, and severe respiratory symptoms: • With evidence of respiratory decompensation ≤7 days before start of study medication, meeting one of the following: • Tach
Slide 16: COVA: evaluating prevention of further respiratory deterioration linked to COVID-19
16 COVA : Sarconeos (BI0101 ) evaluating prevention of further respiratory deterioration linked to COVID - 19 Product 2020 2021 350 mg b.i.d of Sarconeos (BIO101) COVA Study • This is a P hase 2/3 seamless study design • Global , multi - cent er • Double - blind, placebo controlled • Group sequentia
Slide 17: Key milestones
Key milestones □ COVA started in Belgium, Brazil, France and US □ COVA completion of patient enrollment (Part 1 ) in January 2021 □ COVA interim analysis of Part 1 expected in Q 1 2021 □ COVA IRB approvals for Part 2 in all the respective jurisdictions □ COVA completion of patient enrollment (Part 2
Slide 18: Thank you
18 Thank you CONTACTS: ▪ Stanislas Veillet – CEO stanislas.veillet@biophytis.com ▪ Evelyne NGUYEN – CFO evelyne.nguyen@biophytis.com EPA: ALBPS Proposed Nasdaq trading symbol: “BPTS”